Status:
UNKNOWN
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
Lead Sponsor:
Indonesia University
Conditions:
Multiple System Atrophy
Parkinsonism
Eligibility:
All Genders
Phase:
NA
Brief Summary
The prevalence of Multiple System Atrophy (MSA) is reported to be between 3.4 - 4.9 cases per 100,000 population. The estimated average incidence is 0.6 - 0.7 cases per 100,000 people per year. Many p...
Eligibility Criteria
Inclusion
- Patients developed MSA based on clinical examination and consensus MSA criteria.
- Patients diagnosed with MSA for less than 4 years.
- Patients with an anticipated survival of at least 3 years in the opinion of the examiner.
- Patients with MOCa and Mini Mental State Examination (MMSE) values of more than 24.
- For Adipose Autologous-MSC group subjects were not experiencing active infection, which was confirmed by screening for HbSAg, Anti HCV, Syphilis, HIV, CMV, Rubella, and Toxoplasma.
- Subjects are willing to participate in research and fill out an informed consent form.
- Do not have autoimmune disorder, or undergoes management disorders and / or other diseases related to MSA
- Subjects are willing to participate in research and fill out an informed consent form.
Exclusion
- Suffer from systemic autoimmune diseases (systemetic lupus erythomatosus, Addison's disease, Crohn's disease, arthritis management), immunodeficiency (SIDA), or blood clotting disorders or management of malignant diseases (diseases associated with MSA)
- Undergo immunosuppressive therapy, anticoagulants or corticosteroids.
- Patients with malignant neoplasms and close family history of neoplasms.
- already had history of spinal surgery, have paralysis or have spinal diseases.
- Patients with a history of electroconvulsive therapy.
- Patients with a history of brain surgery for Parkinson's disease.
- Patients with systemic or local infections located close to the injection site.
- Undergo immunosuppressive therapy, anticoagulants or corticosteroids.
- The patient was not willing to take part in the study and did not fill out informed consent.
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 5 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04876326
Start Date
October 5 2020
End Date
October 5 2021
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia